Table 1.
Characteristics of the included studies.
| Author (year) | Cancer type | Study Phase | Patients analyzed | Patients per arm | Treatment line | Median age (year) | Drug, dosage (mg/m2) and schedule | Study region | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Gradishar (2005)2 | MBC | III | 454 | 229 | 1st line 42% | 53.1 | nab-paclitaxel | 260 | q3w | Russia, Ukraine, USA, Canada, UK |
| 225 | 1st line 40% | 53.3 | sb-paclitaxel | 175 | q3w | China | ||||
| Guan (2009)3 | MBC | II | 210 | 104 | 1st line 59% | 50.0 | nab-paclitaxel | 260 | q3w | |
| 106 | 1st line 60% | 48.5 | sb-paclitaxel | 175 | q3w | |||||
| Gradishar4,5 (2009 + 2012) | MBC | II | 300 | 76 | 1st line 100% | 51.7 | nab-paclitaxel | 300 | q3w | Russia, USA |
| 76 | 55.4 | nab-paclitaxel | 100 | qw3/4 | ||||||
| 74† | 53.3 | nab-paclitaxel | 150 | qw3/4 | ||||||
| 74† | 55.4 | docetaxel | 100 | q3w | ||||||
| Rugo (2015)* 6 | MBC | III | 783 | 267† | 1st line 100% | 54.3 | nab-paclitaxel | 150 | qw3/4 | USA |
| 241 | 54.7 | ixabepilone | 16 | qw3/4 | ||||||
| 275† | 55.1 | sb-paclitaxel | 90 | qw3/4 | ||||||
| Tamura (2017)10 | MBC | II | 200 | 100 | 1st line 73% | 60.0 | nab-paclitaxel | 150 | qw3/4 | Japan |
| 100 | 1st line 70% | 58.0 | docetaxel | 75 | q3w | |||||
*Patients in each arm of Rugo (2015) were also administered with bevacizumab 10 mg/kg (q2w) in addition to the study drug.
†Selected arms for this study.
Abbreviations: nab, nanoparticle albumin-bound; sb, solvent-based; MBC, metastatic breast cancer; q3w, every 3 weeks; qw3/4, first 3 of 4 weeks; q2w, every 2 weeks.